Myriad Genetics Inc
MYGN Real Time Price USDRecent trades of MYGN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MYGN's directors and management
Government lobbying spending instances
-
$290,000 Apr 18, 2025 Issue: Medicare/Medicaid Insurance
-
$290,000 Jan 17, 2025 Issue: Medicare/Medicaid
-
$290,000 Oct 17, 2024 Issue: Medicare/Medicaid
-
$290,000 Jul 19, 2024 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$290,000 Apr 22, 2024 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$290,000 Jan 22, 2024 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$210,000 Oct 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations
-
$210,000 Jul 17, 2023 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$290,000 Jan 20, 2023 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$210,000 Oct 19, 2022 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$180,000 Jul 20, 2022 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$290,000 Apr 20, 2022 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$200,000 Jan 20, 2022 Issue: None
-
$160,000 Oct 20, 2021 Issue: None
-
$170,000 Jul 20, 2021 Issue: None
-
$240,000 Apr 20, 2021 Issue: None
-
$210,000 Jan 20, 2021 Issue: None
-
$156,000 Oct 20, 2020 Issue: None
-
$130,000 Jul 20, 2020 Issue: None
-
$220,000 Apr 20, 2020 Issue: None
-
$240,000 Jan 21, 2020 Issue: None
-
$260,000 Oct 21, 2019 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues Budget/Appropriations
-
$170,000 Jul 22, 2019 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Copyright/Patent/Trademark Health Issues Medicare/Medicaid
-
$240,000 Apr 22, 2019 Issue: Medical/Disease Research/Clinical Labs Copyright/Patent/Trademark Medicare/Medicaid
-
$230,000 Jan 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Copyright/Patent/Trademark
-
$60,000 Oct 18, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Veterans
Estimated quarterly lobbying spending
MYGN Revenue by Segment or Geography
New patents grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to MYGN
Recent picks made for MYGN stock on CNBC
ETFs with the largest estimated holdings in MYGN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MYGN stock a Buy, Sell, or Hold?
- What is the price target for $MYGN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MYGN stock?
- Who owns the most shares of $MYGN stock?
- What funds own $MYGN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MYGN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.